Abstract
Nivolumab, a monoclonal antibody targeting the PD-1, has recently been used as a standard treatment for lung cancer, melanoma and renal cell carcinoma. We herein report the case of a patient undergoing treatment for non-small cell lung cancer (NSCLC) who developed interstitial pneumonia which featured nivolumab-induced granuloma formation. An 82-year-old male patient with NSCLC was initially treated with radiation therapy and chemotherapy. Five years later, however, he developed metastatic carcinoma in a hilar lymph node accompanied by ground glass opacity (GGO), suggesting tumor cell invasion. Treatment with nivolumab was initiated. At 21 days after the first dose of nivolumab, he complained of cough and dyspnea. Chest computed tomography scans demonstrated tumor progression and newly formed GGO in the area surrounding the primary tumor. Fibrosing active alveolitis with granuloma formation and organizing pneumonia findings were observed in the pathological examination of a transbronchial lung biopsy (TBLB) specimen. No malignant cells were found in TBLB. A bacteriological analysis of cultures, a PCR, and special staining did not reveal any infections. The patient’s pneumonitis improved after treatment with systemic corticosteroids. Granuloma-forming interstitial pneumonia may be a feature of nivolumab-associated pneumonitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Keir ME, Butte MJ, Freeman GJ et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704
Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639
Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330
Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813
Gettinger S, Rizvi NA, Chow LQ et al (2016) Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34(25):2980–2987
Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135
Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454
Nishino M, Sholl LM, Hodi FS et al (2015) Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373(3):288–290
Nakashima K, Naito T, Omori S et al (2016) Organizing pneumonia induced by nivolumab in a patient with metastatic melanoma. J Thorac Oncol 11(3):432–433
Sano T, Uhara H, Mikoshiba Y et al (2016) Nivolumab-induced organizing pneumonia in a melanoma patient. Jpn J Clin Oncol 46(3):270–272
Naidoo J, Wang X, Woo KM et al (2016) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35(7):709–717
Gettinger SN, Zhang X, Homer RJ et al (2016) Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. J Clin Oncol 34(suppl):abstr 9030
Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541–3543
Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58(8):1297–1306
Koelzer VH, Rothschild SI, Zihler D et al (2016) Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 4:13
Danlos FX, Pages C, Baroudjian B et al (2016) Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest 149(5):e133–e136
Hasleton P, Flieder DB (2013) Spencer’s Pathology of the Lung, 6th edn. Cambridge University Press, New York
Saito Y, Kunugi S, Suzuki Y et al (2013) Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy. Intern Med 52(2):263–267
Braun NA, Celada LJ, Herazo-Maya JD et al (2014) Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Am J Respir Crit Care Med 190(5):560–571
Palmer BE, Mack DG, Martin AK et al (2008) Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease. J Immunol 180(4):2704–2712
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kashiwada, T., Saito, Y., Minegishi, Y. et al. Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung. Int Canc Conf J 6, 131–134 (2017). https://doi.org/10.1007/s13691-017-0291-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-017-0291-0